健脾软肝药糊辅助治疗慢性乙型肝炎肝纤维化临床效果  

Clinical effect of Jianpiruangan drug in adjuvant treatment of chronic hepatitis B liver fibrosis

作　　者：陈凯伟 王庆莲 王建平 邵岩峰 林友宁 CHEN Kaiwei;WANG Qinglian;WANG Jianping(Comprehensive Internal Medicine,The Third People's Hospital of Fujian University of Traditional Chinese Medicine,Fujian Province,Fuzhou 350108,China)

机构地区：[1]福建中医药大学附属第三人民医院综合内科,福州市350108 [2]福建中医药大学附属第三人民医院脾胃病科,福州市350108 [3]福建中医药大学附属第三人民医院肝病科,福州市350108

出　　处：《临床合理用药杂志》2021年第7期36-38,共3页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察健脾软肝药糊辅助治疗慢性乙型肝炎肝纤维化的临床效果。方法选取2017年1月-2019年1月福建中医药大学附属第三人民医院收治的慢性乙型肝炎肝纤维化患者40例,采用随机数字表法分为研究组和对照组,每组20例。在对症支持治疗的基础上,对照组予以恩替卡韦胶囊治疗,研究组在对照组的基础上加用健脾软肝药糊治疗。比较2组治疗前后肝功能指标[丙氨酸氨基转移酶(ALT)、白蛋白(ALB)、总胆红素(TBIL)]、肝纤维化指标[透明质酸(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PC-Ⅲ)、Ⅳ型胶原(C-Ⅳ)]及不良反应。结果治疗后,2组ALT、ALB、TBIL均优于治疗前,且研究组ALB、TBIL均优于对照组(P<0.05),但治疗后2组ALT比较差异无统计学意义(P>0.05)。治疗后,2组HA、LN、PC-Ⅲ及C-Ⅳ均低于治疗前,且研究组低于对照组(P<0.05)。2组不良反应总发生率比较差异无统计学意义(χ^(2)=0.229,P=0.633)。结论健脾软肝药糊辅助治疗慢性乙型肝炎肝纤维化有利于改善患者肝功能及肝纤维化,且安全性较高,值得推广应用。Objective To study the clinical effect of Jianpiruangan drug in adjuvant treatment of chronic hepatitis B liver fibrosis.Methods From January 2017 to January 2019,40 patients with chronic hepatitis B liver fibrosis admitted to the Third People’s Hospital of Fujian University of Traditional Chinese Medicine were selected,and they were divided into study group and control group using a random number table method,with 20 cases in each group.On the basis of symptomatic and supportive treatment,the control group was treated with entecavir capsules,and the study group was treated with Jianpiruangan paste on the basis of the control group.Compared the liver function indexes[alanine aminotransferase(ALT),albumin(ALB),total bilirubin(TBIL)],liver fibrosis indexes[hyaluronic acid(HA),laminin(LN),ⅢProcollagen(PC-Ⅲ),Ⅳcollagen(C-Ⅳ)]and adverse reactions.Results After treatment,the ALT,ALB,and TBIL of the two groups were better than those before treatment,and the ALB and TBIL of the study group were better than those of the control group(P<0.05),but there was no significant difference in ALT between the two groups after treatment(P>0.05).After treatment,HA,LN,PC-Ⅲand C-Ⅳin the two groups were lower than before treatment,and the study group was lower than the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(χ^(2)=0.229,P=0.633).Conclusion The adjuvant treatment of Jianpiruangan drug for the treatment of chronic hepatitis B liver fibrosis is beneficial to improve the liver function and liver fibrosis of patients,and has high safety.

关 键 词：乙型肝炎 慢性 肝纤维化 健脾软肝药糊 恩替卡韦 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]